Annexon, Inc.
ANX1502
Autoimmune Disease
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for ANX1502 in Autoimmune Disease are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Update on POC Trial in CAD Anticipated in 2026”